Mesenchymal stem cells attenuate inflammatory processes in the heart and lung via inhibition of TNF signaling

Basic Research in Cardiology

Volumn 111, Issue 5, 2016, Pages

  Martire, Alessandra ^a   Bedada, Fikru B ^a   Uchida, Shizuka ^a   Pöling, Jochen ^a,c   Krüger, Marcus ^a   Warnecke, Henning ^b,c   Richter, Manfred ^d   Kubin, Thomas ^a   Herold, Susanne ^e   Braun, Thomas ^a  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c Schuchtermann Klinik   (Germany)

^d KERCKHOFF HEART CENTER   (Germany)

^e JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Acute lung injury; Fibrosis; Heart failure; Inflammation; Mesenchymal stem cells; Proteomics; TNF

Indexed keywords

RECOMBINANT RECEPTOR; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ACUTE LUNG INJURY; ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CARDIAC MUSCLE CELL; CARDITIS; CELL HOMING; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CYTOKINE RELEASE; HISTOPATHOLOGY; LIFESPAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PARACRINE SIGNALING; PNEUMONIA; SIGNAL TRANSDUCTION; TISSUE REACTION; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; ANIMAL; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; HEART; IMMUNOLOGY; INFLAMMATION; LUNG; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PROCEDURES; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARDIOMYOPATHY, DILATED; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; HEART; INFLAMMATION; LUNG; MASS SPECTROMETRY; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84978975346     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-016-0573-2     Document Type: Article

References (41)

1. Apostolaki M, Armaka M, Victoratos P, Kollias G (2010) Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr Dir Autoimmun 11:1–26. doi:10.1159/000289195
2. Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717–1725. doi:10.1056/NEJM199606273342607
3. Belema Bedada F, Technau A, Ebelt H, Schulze M, Braun T (2005) Activation of myogenic differentiation pathways in adult bone marrow-derived stem cells. Mol Cell Biol 25:9509–9519. doi:10.1128/MCB.25.21.9509-9519.2005
4. Belema-Bedada F, Uchida S, Martire A, Kostin S, Braun T (2008) Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2. Cell Stem Cell 2:566–575. doi:10.1016/j.stem.2008.03.003
5. Bernardo Maria E, Fibbe Willem E (2013) Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 13:392–402. doi:10.1016/j.stem.2013.09.006
6. Beyaert R, Fiers W (1998) Tumor necrosis factor and lymphotoxin. In: Mire-Sluis A, Thorpe R (eds) Cytokines. Academic Press, San Diego, pp 335–360
7. Boettger T, Beetz N, Kostin S, Schneider J, Kruger M, Hein L, Braun T (2009) Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 119:2634–2647. doi:10.1172/JCI38864
8. Bozkurt B, Mann DL, Deswal A (2010) Biomarkers of inflammation in heart failure. Heart Fail Rev 15:331–341. doi:10.1007/s10741-009-9140-3
9. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, Mann DL (2001) Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 103:1044–1047
10. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Mann DL (1999) Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 99:3224–3226
11. Ebelt H, Jungblut M, Zhang Y, Kubin T, Kostin S, Technau A, Oustanina S, Niebrugge S, Lehmann J, Werdan K, Braun T (2007) Cellular cardiomyoplasty: improvement of left ventricular function correlates with the release of cardioactive cytokines. Stem Cells 25:236–244. doi:10.1634/stemcells.2006-0374
12. Herold S, Tabar TS, Janßen H, Hoegner K, Cabanski M, Lewe-Schlosser P, Albrecht J, Driever F, Vadasz I, Seeger W, Steinmueller M, Lohmeyer J (2011) Exudate macrophages attenuate lung injury by the release of IL-1 receptor antagonist in gram-negative pneumonia. Am J Respir Crit Care Med 183:1380–1390. doi:10.1164/rccm.201009-1431OC
13. Hou Y, Adrian-Segarra JM, Richter M, Kubin N, Shin J, Werner I, Walther T, Schonburg M, Poling J, Warnecke H, Braun T, Kostin S, Kubin T (2015) Animal models and “Omics” technologies for identification of novel biomarkers and drug targets to prevent heart failure. BioMed Res Int 2015:10. doi:10.1155/2015/212910
14. Jiang Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM (2002) Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol 30:896–904
15. Keating A (2012) Mesenchymal stromal cells: new directions. Cell Stem Cell 10:709–716. doi:10.1016/j.stem.2012.05.015
16. Kolattukudy PE, Quach T, Bergese S, Breckenridge S, Hensley J, Altschuld R, Gordillo G, Klenotic S, Orosz C, Parker-Thornburg J (1998) Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am J Pathol 152:101–111
17. Kruger M, Moser M, Ussar S, Thievessen I, Luber CA, Forner F, Schmidt S, Zanivan S, Fassler R, Mann M (2008) SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 134:353–364. doi:10.1016/j.cell.2008.05.033
18. Larson AC, White RD, Laub G, McVeigh ER, Li D, Simonetti OP (2004) Self-gated cardiac cine MRI. Magn Reson Med 51:93–102. doi:10.1002/mrm.10664
19. Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236–241. doi:10.1056/NEJM199007263230405
20. Lorchner H, Poling J, Gajawada P, Hou Y, Polyakova V, Kostin S, Adrian-Segarra JM, Boettger T, Wietelmann A, Warnecke H, Richter M, Kubin T, Braun T (2015) Myocardial healing requires Reg3beta-dependent accumulation of macrophages in the ischemic heart. Nat Med 21:353–362. doi:10.1038/nm.3816
21. Madrigal M, Rao K, Riordan N (2014) A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. J Transl Med 12:260
22. Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 109:1594–1602. doi:10.1161/01.cir.0000124490.27666.b2
23. Martire A, Fernandez B, Buehler A, Strohm C, Schaper J, Zimmermann R, Kolattukudy PE, Schaper W (2003) Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice mimics ischemic preconditioning through SAPK/JNK1/2 activation. Cardiovasc Res 57:523–534. doi:10.1016/S0008-6363(02)00697-1
24. Mauney JR, Volloch V, Kaplan DL (2005) Role of adult mesenchymal stem cells in bone tissue engineering applications: current status and future prospects. Tissue Eng 11:787–802. doi:10.1089/ten.2005.11.787
25. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI (2009) Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 20:419–427. doi:10.1016/j.cytogfr.2009.10.002
26. Menasché P (2011) Stem cell therapy for chronic heart failure. Lessons from a 15-year experience. Comptes Rendus Biol 334:489–496. doi:10.1016/j.crvi.2011.03.006
27. Mukhopadhyay S, Hoidal J, Mukherjee T (2006) Role of TNFalpha in pulmonary pathophysiology. Respir Res 7:125
28. Narita T, Suzuki K (2015) Bone marrow-derived mesenchymal stem cells for the treatment of heart failure. Heart Fail Rev 20:53–68. doi:10.1007/s10741-014-9435-x
29. Ohishi M, Schipani E (2010) Bone marrow mesenchymal stem cells. J Cell Biochem 109:277–282. doi:10.1002/jcb.22399
30. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P (2001) Bone marrow cells regenerate infarcted myocardium. Nature 410:701–705. doi:10.1038/35070587
31. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, Werner C (2004) Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22:377–384. doi:10.1634/stemcells.22-3-377
32. Parekkadan B, Milwid JM (2010) Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 12:87–117. doi:10.1146/annurev-bioeng-070909-105309
33. Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views. Stem Cells 25:2896–2902. doi:10.1634/stemcells.2007-0637
34. Poling J, Gajawada P, Richter M, Lorchner H, Polyakova V, Kostin S, Shin J, Boettger T, Walther T, Rees W, Wietelmann A, Warnecke H, Kubin T, Braun T (2014) Therapeutic targeting of the oncostatin M receptor-beta prevents inflammatory heart failure. Basic Res Cardiol 109:396. doi:10.1007/s00395-013-0396-3
35. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G (1995) Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci USA 92:11294–11298
36. Prockop DJ (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276:71–74. doi:10.1126/science.276.5309.71
37. Schulze M, Belema-Bedada F, Technau A, Braun T (2005) Mesenchymal stem cells are recruited to striated muscle by NFAT/IL-4-mediated cell fusion. Genes Dev 19:1787–1798. doi:10.1101/gad.339305
38. Sweeney RM, Griffiths M, McAuley D (2013) Treatment of acute lung injury: current and emerging pharmacological therapies. Semin Respir Crit Care Med 34:487–498. doi:10.1055/s-0033-1351119
39. Togel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C (2007) Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 292:F1626–F1635. doi:10.1152/ajprenal.00339.2006
40. Vogel S, Kubin T, von der Ahe D, Deindl E, Schaper W, Zimmermann R (2006) MEK hyperphosphorylation coincides with cell cycle shut down of cultured smooth muscle cells. J Cell Physiol 206:25–34. doi:10.1002/jcp.20437
41. Wei X, Yang X, Han Z-p Qu, F-f Shao L, Y-f Shi (2013) Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin 34:747–754. doi:10.1038/aps.2013.50